Welcome to
On Feet Nation
Melissa Online
Agatha Online
sara James Online
Posted by Agatha on August 23, 2024 at 10:17am 0 Comments 0 Likes
Posted by sara James on August 23, 2024 at 10:15am 0 Comments 0 Likes
The global Upper Extremity Implants Market size is anticipated to reach USD 2.28 billion by 2030 and is projected to grow at a CAGR of 4.0% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of musculoskeletal disorders significantly influences the upper extremity implant market. Conditions such as arthritis,…
ContinueThe global Cancer Gene Therapy Market size is expected to reach USD 12.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.9% from 2024 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite’s Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.
The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.
The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.
Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.
List of Key Players of Cancer Gene Therapy Market
Related Press Release@ Cancer Gene Therapy Market Report
Cancer Gene Therapy Market Report Highlights
Report Attribute |
Details |
Market size value in 2024 |
USD 4.51 billion |
Revenue forecast in 2030 |
USD 12.76 billion |
Growth rate |
CAGR of 18.9% from 2024 to 2030 |
Actual data |
2018 - 2023 |
Forecast period |
2024 - 2030 |
Cancer Gene Therapy Market Segmentation
Grand View Research has segmented the global cancer gene therapy market based on therapy, end-use, and region:
Product Therapy Outlook (Revenue, USD Million, 2018 - 2030)
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Region Outlook (Revenue, USD Million, 2018 - 2030)
Explore Horizon, the world's most expansive market research database
© 2024 Created by PH the vintage.
Powered by
You need to be a member of On Feet Nation to add comments!
Join On Feet Nation